share_log

騰盛博藥-B：截至2023年12月31日止年度之年度業績公告

BRII-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

香港交易所 ·  Mar 22 19:00
Summary by Futu AI
騰盛博藥-B（BRII-B）公布截至2023年12月31日止年度業績，銀行存款及現金減少11.3%，研發開支下降8.6%，主因COVID-19項目終止。其他收入增加51.7%，得益於存款利率上升。公司積極推進乙型肝炎病毒項目，並於2024年2月獲得BRII-179全部知識產權，提升生產能力。未來將啟動HBV功能性治癒項目後期臨床試驗，並尋求外部合作推進MDR/XDR、HIV及CNS項目。公司調整執行團隊，優化資源配置，保留穩健現金儲備支持長期運營。
騰盛博藥-B（BRII-B）公布截至2023年12月31日止年度業績，銀行存款及現金減少11.3%，研發開支下降8.6%，主因COVID-19項目終止。其他收入增加51.7%，得益於存款利率上升。公司積極推進乙型肝炎病毒項目，並於2024年2月獲得BRII-179全部知識產權，提升生產能力。未來將啟動HBV功能性治癒項目後期臨床試驗，並尋求外部合作推進MDR/XDR、HIV及CNS項目。公司調整執行團隊，優化資源配置，保留穩健現金儲備支持長期運營。
TENSENG PHARMACEUTICALS - B (BRII-B) ANNOUNCED ITS RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023, WITH BANK DEPOSITS AND CASH DOWN 11.3% AND R&D EXPENDITURE DOWN 8.6% DUE TO THE TERMINATION OF COVID-19 PROJECTS. Other income increased 51.7%, driven by higher deposit rates. The company actively promoted the hepatitis B virus project and acquired all intellectual property rights to BRII-179 in February 2024 to increase its production capacity. In the future, post-clinical trials of HBV functional cure projects will be launched and external cooperation will be sought to advance MDR/XDR, HIV and CNS projects. The company realigns its executive team, optimizes resource allocation, maintains a stable cash reserve to support long-term operations.
TENSENG PHARMACEUTICALS - B (BRII-B) ANNOUNCED ITS RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023, WITH BANK DEPOSITS AND CASH DOWN 11.3% AND R&D EXPENDITURE DOWN 8.6% DUE TO THE TERMINATION OF COVID-19 PROJECTS. Other income increased 51.7%, driven by higher deposit rates. The company actively promoted the hepatitis B virus project and acquired all intellectual property rights to BRII-179 in February 2024 to increase its production capacity. In the future, post-clinical trials of HBV functional cure projects will be launched and external cooperation will be sought to advance MDR/XDR, HIV and CNS projects. The company realigns its executive team, optimizes resource allocation, maintains a stable cash reserve to support long-term operations.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.